967 results on '"Pisters, Peter"'
Search Results
2. MD Anderson’s 10-year experience with regional surgical oncology in the Houston area locations
3. ASO Visual Abstract: Impact of Cancer Care Regionalization on Patient Volume
4. Comparative Age-Based Prospective Multi-Institutional Observations of 12,367 Patients Enrolled to the American College of Surgeons Oncology Group (ACOSOG) Z901101 Trials (Alliance)
5. Perioperative Gemcitabine + Erlotinib Plus Pancreaticoduodenectomy for Resectable Pancreatic Adenocarcinoma: ACOSOG Z5041 (Alliance) Phase II Trial
6. Borderline Resectable Pancreatic Cancer: Need for Standardization and Methods for Optimal Clinical Trial Design
7. Serum CA 19-9 as a Marker of Resectability and Survival in Patients with Potentially Resectable Pancreatic Cancer Treated with Neoadjuvant Chemoradiation
8. Long-Term Survival After Multidisciplinary Management of Resected Pancreatic Adenocarcinoma
9. Disease-free Survival and Local Recurrence for Laparoscopic Resection Compared With Open Resection of Stage II to III Rectal Cancer: Follow-up Results of the ACOSOG Z6051 Randomized Controlled Trial
10. Impact of Cancer Care Regionalization on Patient Volume
11. Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience
12. Preoperative (Neoadjuvant) Therapy for Resectable Adenocarcinoma of the Pancreas
13. Regional Lymph Node Dissection for Pancreatic Adenocarcinoma
14. A flexible‐hazards cure model with application to patients with soft tissue sarcoma
15. Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer
16. Predicting the risks of venous thromboembolism versus post-pancreatectomy haemorrhage: analysis of 13 771 NSQIP patients
17. Stromal Tumors of the Small Bowel
18. Soft Tissue Sarcoma
19. Total Parenteral Nutrition in Cancer
20. Enteral Nutrition in Cancer
21. Novel Chemoradiation in Localized Pancreatic Cancer: Clinical Studies
22. Gastric Cancer
23. Staging and Therapeutic Approaches for Patients with Localized, Potentially Curable Pancreatic Adenocarcinoma
24. Impact of an interdisciplinary goals of care program on hospital outcomes at a comprehensive cancer center during the COVID-19 pandemic: A propensity score analysis.
25. Preoperative therapy for soft tissue sarcoma
26. Loss of phosphatase and tensin homolog expression is associated with recurrence and poor prognosis in patients with pancreatic ductal adenocarcinoma
27. Soft Tissue Sarcoma
28. Soft Tissue Sarcoma
29. Neoadjuvant Therapy is Associated with a Reduced Lymph Node Ratio in Patients with Potentially Resectable Pancreatic Cancer
30. Risk of venous thromboembolism outweighs post-hepatectomy bleeding complications: analysis of 5651 National Surgical Quality Improvement Program patients
31. Microscopically Positive Margins for Primary Gastrointestinal Stromal Tumors: Analysis of Risk Factors and Tumor Recurrence
32. Yield of clinical and radiographic surveillance in patients with resected pancreatic adenocarcinoma following multimodal therapy
33. Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma is associated with a better prognosis
34. Standard Forms of Pancreatic Resection
35. Advances in the diagnosis and treatment of adenocarcinoma of the pancreas
36. New developments in soft tissue sarcoma
37. Resection of the Superior Mesenteric-Portal Vein Confluence During Pancreaticoduodenectomy
38. Multicystic dedifferentiated retroperitoneal liposarcoma: tumour cyst fluid analysis and implications for management
39. Analysis of Prognostic Factors Impacting Oncologic Outcomes After Neoadjuvant Tyrosine Kinase Inhibitor Therapy for Gastrointestinal Stromal Tumors
40. Locoregional Disease Patterns in Well-Differentiated and Dedifferentiated Retroperitoneal Liposarcoma: Implications for the Extent of Resection?
41. Radiographic Tumor–Vein Interface as a Predictor of Intraoperative, Pathologic, and Oncologic Outcomes in Resectable and Borderline Resectable Pancreatic Cancer
42. Morbidity and Mortality after Pancreaticoduodenectomy in Patients with Borderline Resectable Type C Clinical Classification
43. Treatment Sequencing for Resectable Pancreatic Cancer: Influence of Early Metastases and Surgical Complications on Multimodality Therapy Completion and Survival
44. Impact of an Interdisciplinary Goals-of-Care Program Among Medical Inpatients at a Comprehensive Cancer Center During the COVID-19 Pandemic: A Propensity Score Analysis.
45. Phase 1 Adaptive Dose-Finding Study of Neoadjuvant Gemcitabine Combined With Radiation Therapy for Patients With High-Risk Extremity and Trunk Soft Tissue Sarcoma
46. Effect of Laparoscopic-Assisted Resection vs Open Resection of Stage II or III Rectal Cancer on Pathologic Outcomes: The ACOSOG Z6051 Randomized Clinical Trial
47. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
48. Frequency and Intensity of Postoperative Surveillance After Curative Treatment of Pancreatic Cancer: A Cost-Effectiveness Analysis
49. Fear of Cancer Recurrence after Curative Pancreatectomy: A Cross-sectional Study in Survivors of Pancreatic and Periampullary Tumors
50. Improving Goal Concordant Care Among 10 Leading Academic U.S. Cancer Hospitals: A Collaboration of the Alliance of Dedicated Cancer Centers
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.